Abstract | OBJECTIVES: BACKGROUND: Inhibition of platelet aggregation with monoclonal antibody c7E3 Fab directed against glycoprotein ( GP) IIb/IIIa has been shown to reduce ischemic complications after angioplasty and is being considered for treatment of other acute ischemic syndromes. METHODS: Patients undergoing elective coronary angioplasty received aspirin (325 mg orally), heparin (12,000 U intravenously) and a bolus of c7E3 Fab (0.25 mg/kg body weight). Surface GPIIb/IIIa receptor blockade and aggregation in response to 20 mumol/liter ADP, 5 micrograms/ml collagen and 7.5 and 15 mumol/liter TRAP were assessed. RESULTS: Surface GPIIb/IIIa receptor blockade by c7E3 Fab was 80% 2 h after injection and decreased to 50% at 24 h. Platelet aggregation in response to 20 mumol/liter ADP was inhibited by 73% at 2 h, and this inhibition decreased to 27% at 24 h. Platelet aggregation in response to 7.5 mumol/liter TRAP was inhibited by 53% at 2 h and 30% at 24 h. In contrast, aggregation in response to 15 mumol/liter TRAP was inhibited only 37% at 2 h and 10% at 24 h (p < 0.001 and p = 0.006, respectively vs. 20 mumol/liter ADP). Addition of exogenous c7E3 Fab to platelet-rich plasma led to more complete inhibition of 7.5 mumol/liter TRAP-induced aggregation. CONCLUSIONS:
|
Authors | N S Kleiman, A E Raizner, R Jordan, A L Wang, D Norton, K F Mace, A Joshi, B S Coller, H F Weisman |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 26
Issue 7
Pg. 1665-71
(Dec 1995)
ISSN: 0735-1097 [Print] United States |
PMID | 7594101
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- ITGA2B protein, human
- Immunoglobulin Fab Fragments
- Integrin alpha2
- Membrane Glycoproteins
- Oligopeptides
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIb-IX Complex
- Platelet Membrane Glycoproteins
- Receptors, Cell Surface
- glycoprotein GP III
- glycoprotein receptor GPIb-IX
- thrombin receptor-activating peptide SFLLRNPNDKY
- Adenosine Diphosphate
- Abciximab
|
Topics |
- Abciximab
- Adenosine Diphosphate
(pharmacology)
- Adult
- Aged
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Female
- Humans
- Immunoglobulin Fab Fragments
(pharmacology, therapeutic use)
- Integrin alpha2
- Male
- Membrane Glycoproteins
(blood)
- Middle Aged
- Oligopeptides
(pharmacology)
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(pharmacokinetics, pharmacology, therapeutic use)
- Platelet Glycoprotein GPIb-IX Complex
(antagonists & inhibitors)
- Platelet Membrane Glycoproteins
- Receptors, Cell Surface
(antagonists & inhibitors)
|